Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e39-e40. doi: 10.1111/jdv.14486. Epub 2017 Aug 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Female
  • Humans
  • Ipilimumab / therapeutic use*
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Melanoma / drug therapy*
  • Melanoma / secondary
  • Nivolumab / therapeutic use*
  • Response Evaluation Criteria in Solid Tumors
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Vaginal Neoplasms / drug therapy*
  • Vaginal Neoplasms / secondary
  • Vulvar Neoplasms / drug therapy*
  • Vulvar Neoplasms / secondary

Substances

  • Antineoplastic Agents, Immunological
  • Ipilimumab
  • Nivolumab